Eisai To Submit Breast Cancer Drug Eribulin NDA In FY2009
This article was originally published in PharmAsia News
Executive Summary
Eisai president Haruo Naito disclosed that the company will submit a new drug application in Japan, the U.S. and Europe for E7389 (eribulin), for advanced breast cancer in patients who have been previously treated with anthracyclines, taxanes and capecitabine